IRF2 and neoplasm: Overall, mutated-β-catenin represses IRF2, POU2F1, and likely other TFs, which limits transcription of key signaling molecules (i.e., cytokines and chemokines) important for priming lymphocyte recruitment needed for effective anti-tumor immunity.